Table 1.
Patient and donor characteristics.
| Criteria | Group 1 (non-GVHD) | Group 2 (GVHD) |
|---|---|---|
| Patients, n | 7 | 7 |
| Recipient | ||
| Age at HSCT (median (range)) | 47 (30–58) | 51 (36–64) |
| Gender, n (female/male) | 3/4 | 3/4 |
| Diagnosis, n | ||
| AML | 1 | 3 |
| ALL | 2 | 0 |
| CLL | 1 | 0 |
| MDS/MPD | 3 | 2 |
| Solid tumour | 0 | 2 |
| Donor | ||
| HLA-identical sibling, n | 7 | 7 |
| Age at HSCT (median (range)) | 40 (31–67) | 54 (43–68) |
| Conditioning regimen, n | ||
| Cy + fTBI | 2 | 0 |
| Cy + Bu | 2 | 4 |
| Flu + Bu | 2 | 1 |
| Flu + Cy | 0 | 2 |
| Cy + fTBI + Flu | 1 | 0 |
| Antithymocyte treatment, n | ||
| ATG | 1 | 0 |
| Campath | 1 | 0 |
| GVHD prophylaxis, n | ||
| CsA + MTX | 7 | 5 |
| FK + RAPA | 0 | 2 |
| Graft source, n | ||
| PBSCs | 7 | 7 |
| Cell dose, median (range) | ||
| Total nucleated cells (×108/kg) | 8.6 (7.5–21.6) | 14.8 (5.0–24.5) |
| CD34+ cells (×106/kg) | 8 (4.7–11) | 9.1 (4.3–9.6) |
AML, acute myeloid leukaemia; ALL, acute lymphoblastic leukaemia; ATG, anti-T-cell globulin; Bu, busulfan; CLL, chronic lymphocytic leukaemia; CsA, cyclosporine A; Cy, cyclophosphamide; FK, tacrolimus; Flu, fludarabine; fTBI, fractionated total body irradiation; GVHD, graft-versus-host disease; HLA, human leukocyte antigen; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorders; MTX, methotrexate; n, number; PBSC, peripheral blood stem cell; RAPA, sirolimus. Statistical analysis was done with the Mann–Whitney U test and Fisher's exact test.